MassMutual Private Wealth & Trust’s Protagonist Therapeutics PTGX Stock Holding History

MassMutual Private Wealth & Trust’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.1K	Buy	131 +6	+5%	+$627	﹤0.01%	1195
2026 Q1	$13.2K	Buy	125 +6	+5%	+$531	﹤0.01%	1258
2025 Q4	$10.4K	Hold	119	–	–	﹤0.01%	1372
2025 Q3	$7.91K	Hold	119	–	–	﹤0.01%	1488
2025 Q2	$6.58K	Buy	119 +74	+164%	+$3.55K	﹤0.01%	1529
2025 Q1	$2.18K	Sell	45 -6	-12%	-$251	﹤0.01%	1892
2024 Q4	$1.97K	Buy	51 +48	+1,600%	+$2.09K	﹤0.01%	1845
2024 Q3	$135	Buy	+3	New	+$121	﹤0.01%	2114

Other funds holding PTGX

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

NFT

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return

AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

MAP

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

LSERS

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return

MassMutual Private Wealth & Trust's PTGX Position: Q2 2026 in Review

MassMutual Private Wealth & Trust increased its Protagonist Therapeutics (PTGX) stake by 4.8% in Q2 2026, buying an estimated $627 and bringing the position to 131 shares worth $16.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1195.

MassMutual Private Wealth & Trust first reported a position in PTGX in Q3 2024 and has held it in 8 quarters since. 82 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

MassMutual Private Wealth & Trust held 131 shares of Protagonist Therapeutics worth $16.1K as of Q2 2026.
MassMutual Private Wealth & Trust bought 6 Protagonist Therapeutics shares in Q2 2026, an estimated $627.
Protagonist Therapeutics made up ﹤0.01% of MassMutual Private Wealth & Trust's portfolio in Q2 2026, its #1195 holding.
MassMutual Private Wealth & Trust first reported a position in Protagonist Therapeutics in Q3 2024 and has held it in 8 quarters since.
82 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on MassMutual Private Wealth & Trust's 13F filing for Q2 2026, filed 2 Jul 2026.